The impact of multimorbidity on the effects of empagliflozin in chronic kidney disease (CKD): exploratory analyses from the EMPA-KIDNEY trial

被引：0
|
作者：
Mayne, Kaitlin [1 ]
机构：
[1] Univ Oxford, Nuffield Dept Populat Hlth, Richard Doll Bldg,Old Rd Campus, Oxford, England
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷
关键词：
D O I：
10.1093/ndt/gfae069.062
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
308
引用
收藏
页数：3
相关论文
共 50 条
  • [21] THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO DIABETIC KIDNEY DISEASE AT BASELINE: PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL
    Tiku, A.
    Pascoe, E.
    Boudville, N.
    Cass, A.
    Dalbeth, N.
    Day, R.
    De Zoysa, J.
    Douglas, B.
    Faull, R.
    Harris, D.
    Hawley, C.
    Jones, G.
    Kanellis, J.
    Palmer, S.
    Perkovic, V.
    Rangan, G.
    Reidlinger, D.
    Robison, L.
    Walker, R.
    Walters, G.
    Johnson, D.
    Badve, S.
    NEPHROLOGY, 2020, 25 : 60 - 60
  • [22] THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO BASELINE KIDNEY FUNCTION: PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL
    Tiku, A.
    Pascoe, E.
    Boudville, N.
    Cass, A.
    Dalbeth, N.
    Day, R. O.
    De Zoysa, J.
    Douglas, B.
    Faull, R.
    Harris, D.
    Hawley, C.
    Jones, G. R.
    Kanellis, J.
    Palmer, S.
    Perkovic, V.
    Rangan, G.
    Reidlinger, D.
    Robison, L.
    Walker, R. J.
    Walters, G.
    Johnson, D. W.
    Badve, S.
    NEPHROLOGY, 2020, 25 : 60 - 60
  • [23] Reduced progression of kidney disease with empagliflozin: results from EMPA-REG OUTCOME
    Wanner, C.
    Inzucchi, S.
    Lachin, J. M.
    Fitchett, D.
    von Eynatten, M.
    Mattheus, M.
    Johansen, O. E.
    Woerle, H. J.
    Broedl, U. C.
    Zinman, B.
    DIABETIC MEDICINE, 2017, 34 : 80 - 81
  • [24] THE IMPACT OF PERCUTANEOUS NEPHROLITHOTOMY IN SOLITARY FUNCTIONING KIDNEY WITH CHRONIC KIDNEY DISEASE (CKD)
    Kurien, A.
    Baishya, R.
    Mishra, S.
    Ganpule, A.
    Sabnis, R.
    Desai, M.
    JOURNAL OF ENDOUROLOGY, 2009, 23 : A76 - A76
  • [25] Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial
    Hadjadj, Samy
    Cooper, Mark E.
    Steubl, Dominik
    Petrini, Michaela
    Hantel, Stefan
    Mattheus, Michaela
    Wanner, Christoph
    Thomas, Merlin C.
    KIDNEY MEDICINE, 2024, 6 (03)
  • [26] Impact of multimorbidity on risk and outcome of stroke: Lessons from chronic kidney disease
    Kelly, Dearbhla M.
    Rothwell, Peter M.
    INTERNATIONAL JOURNAL OF STROKE, 2021, 16 (07) : 758 - 770
  • [27] COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN FOR ADULTS WITH CHRONIC KIDNEY DISEASE (CKD) IN GREECE
    Koulentaki, M.
    Vlahakos, D.
    Tsimihodimos, V
    Smyrnaios, C.
    Delli, E.
    Karpouzos, G.
    Kourlaba, G.
    VALUE IN HEALTH, 2024, 27 (12) : S75 - S75
  • [28] Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam - findings from a modelling study assessing an EMPA-KIDNEY eligible population, using CKD progression model
    Varghese, Lijoy
    Chang, Poh Wan
    Juntarasiripas, Sorrakorn
    Pham, Hien
    Uster, Anastasia
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 836 - 848
  • [29] Empagliflozin and cardiorenal outcomes in patients with non-proteinuric kidney disease in the EMPA-REG OUTCOME trial
    Wanner, C.
    Zinman, B.
    George, J. T.
    Mattheus, M.
    von Eynatten, M.
    Inzucchi, S. E.
    Hauske, S. J.
    DIABETOLOGIA, 2019, 62 : S5 - S5
  • [30] EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL
    Ruggenenti, Piero
    Inzucchi, Silvio
    Zinman, Bernard
    Hantel, Stefan
    Koitka-Weber, Audrey
    von Eynatten, Maximilian
    Wanner, Christoph
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 : 487 - 487
12345